Business Wire

Zero Networks and Palo Alto Networks Announce Integration to Deliver Comprehensive Microsegmentation with Next-Generation Firewalls

Share

Zero Networks, a leader in zero trust security solutions, today announced an integration with Palo Alto Networks, the global cybersecurity leader, to bring comprehensive, zero trust microsegmentation to organizations as part of a hybrid mesh firewall platform. This strategic integration combines Palo Alto Networks Zero Trust Strata Platforms with Zero Networks microsegmentation to provide customers with enhanced network security.

Vulnerability exploitation has increased dramatically in recent years, leaving organizations susceptible to potential breaches. By combining microsegmentation and next-generation firewalls (NGFWs), organizations can achieve defense-in-depth with improved zero trust implementation, granular policy enforcement and stronger threat prevention. Microsegmentation helps contain threats once they're inside the network, while NGFWs provide strong perimeter defense and threat prevention, resulting in a layered approach that significantly enhances the overall security posture of the network. As a result, organizations are empowered with the necessary tools to enforce strict access controls, minimize lateral movement within their network and proactively defend critical assets.

“Microsegmentation is a critical component of a zero trust strategy, but historically, complexity has hindered adoption. Security teams need solutions that not only provide strong protections but also simplify implementation. The partnership between Palo Alto Networks and Zero Networks addresses both aspects,” said John Grady, Principal Analyst at Enterprise Strategy Group. “Zero Networks’ automation engine streamlines microsegmentation by dynamically discovering assets, intelligently grouping them, and generating precise security policies—while Palo Alto Networks’ NGFWs deliver deep traffic inspection and enforcement. This combination reduces the attack surface, enhances threat prevention, and accelerates time to value.”

“Security today isn’t just about keeping threats out—it’s about ensuring they can’t move if they get in. Palo Alto Networks NGFWs provide advanced enforcement both at the perimeter and within the network, while Zero Networks’ automated microsegmentation takes it even further, creating airtight microsegments with least privilege access within the networks,” said Amir Frankel, Co-founder and CTO, Zero Networks. “By combining these capabilities, we’re giving security teams a fully integrated, layered defense that proactively reduces risk and stops lateral movement in its tracks—without adding complexity.”

Rich Campagna, SVP Product Management, Palo Alto Networks, added:“Palo Alto Networks NGFW allows organizations to stay ahead of the most complex threats with ML-powered network security, and microsegmentation is critical to zero trust. Customers tend to adopt either NGFW or a microsegmentation solution, but in today’s complex threat landscape they need both. Our integration with Zero Networks combines our best-in-class NGFW with automated and dynamic microsegmentation, and will be available to all of our NGFW customers to help them enhance their security.”

The integration also enables shared policy constructs across Zero Networks and Palo Alto Networks management consoles, ensuring customers can create segmentation and threat prevention policies consistently to safeguard critical assets. Additionally, it enhances hybrid mesh firewall platforms by seamlessly integrating nondisruptive microsegmentation through agentless deployment for all asset types, whether on-premises or in the cloud. By unifying these capabilities, the approach simplifies security architecture, reduces operational overhead and delivers comprehensive protection against sophisticated cyberthreats.

The integration is slated to be available to joint customers in Palo Alto Networks Q3 FY25. More information on this integration can be found in the joint solution brief.

About Zero Networks

Zero Networks is a pioneer in automated microsegmentation and network security. Our agentless microsegmentation solutions provide effortless deployment, automatically learning and classifying endpoints to generate precise security policies that orchestrate native firewalls. By preventing unauthorized lateral movement, enforcing just-in-time multi-factor authentication for privileged access, and enhancing protection for critical assets, we empower organizations across every sector to strengthen their security posture with minimal effort. For more information, visit www.zeronetworks.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250225736878/en/

Contacts

Media Contact
Taylor Hadley
LaunchTech Communications for Zero Networks
taylor@golaunchtech.com
978-877-2113

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 20:30:00 EEST | Press release

Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were featured in two oral sessions (Investigational immunotherapy; Abstract #1522MO and Developmental therapeutics; Abstract #916O, respectively) at the European Society of Medical Oncology (ESMO) Congress 2025. “The proof-of-concept data highlight the potential of INCA33890 and INCB161734 to address significant medical needs in patients with advanced solid tumors, including MSS colorectal cancer and PDAC,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These results, including the favorable safety profiles as monotherapies, support continued clinical development. We look forward to explori

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 12:15:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual Meeting. The data demonstrated a progression-free survival (PFS) benefit for patients who experienced disease progression while on or after taking a PARP inhibitor (PARPi), a patient population with particularly poor prognosis. The presentation slides can be found here. The company also announced expansion of the Phase 2 BELLA trial in a poster session at ESMO, found here. New relacorilant data presented at ESMO demonstrated a consistent benefit in PARPi subgroups to overcome chemotherapy resistance. Relaco

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release

Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release

Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye